GA-FINEOS
28.1.2021 15:17:12 CET | Business Wire | Press release
FINEOS Corporation (ASX:FCL ) continues to demonstrate its long standing purpose to “help our clients care for the people they serve through the delivery of superior insurance technology” in 2020 with the completion of 8 new installations and 7 major upgrades of the FINEOS Platform . As a leading provider of core systems for life, accident and health insurers globally, FINEOS offers unparalleled core solutions that help carriers become more dynamic, scalable and competitive.
“We are pleased with our performance over the past year, especially given the challenges we all face in these times of COVID,” said Michael Kelly , CEO of FINEOS. “Many of our global clients are actively engaged in brand-new installations, version upgrades and platform migrations. This tells us that our clients see the value of our significant R&D investment made over the past 5 years and indeed are modernizing their core systems in support of their digital transformation. We are grateful to our clients and SI partners for the tremendous implementation and upgrade achievements over the past year.”
By upgrading to the SaaS-based FINEOS Platform, clients will reap the benefits of a more modern and comprehensive unified system for integrated absence, group and voluntary benefits.
“The FINEOS Platform is purpose built to support the Employee Benefits market and therefore provides several advantages to our clients over repurposed P&C core systems,” said Chuck Johnston , CMO of FINEOS. “As a result, our clients enjoy easier installations and upgrades. What’s more, innate policy and customer management capabilities that exist across the entire FINEOS Platform provide consistent product information as well as powerful, frictionless process and workflows across the platform. These foundational capabilities are distinctive to the FINEOS Platform market offerings from claims to Integrated Disability and Absence Management (IDAM) to the full FINEOS AdminSuite which enables clients to move to quote to claim on one system.”
Demonstrated client success metrics include:
- 40% improvement in staff satisfaction in billing and policy admin
- 27% reduction in disability duration
- 10% increase in client on-time contact
- 25% increase in claim settlements per day
- 12% improvement in RTW (Return to Work)
- 93% reduction for claims acceptance time: now accepted within five days of an accident, down from seventy
Since the start of the COVID-19 pandemic, Employee Benefits carriers in North America and protection schemes across the globe have seen increased demand from their customers for new products, remote functionality, and faster processing times that cannot be achieved with legacy systems.
The value of the FINEOS Platform with excellent client support is evident in the company’s long-term partnerships. “Our partnership with FINEOS continues to grow and we are realizing benefits from the FINEOS system, including streamlined processes which enable our managers to focus on providing excellent outcomes to QSuper members,” said Phil Frazer , CEO of QInsure, Australia. “We are excited to continue our partnership with FINEOS to help support our organization’s agility, digital customer experience and our service excellence.”
In North America, where claims and paid leave laws continue to reverberate with change due to COVID, the necessity for carriers to embrace Integrated Disability and Absence Management (IDAM) remains a critical path to future success. Throughout 2020, FINEOS continued to focus on integrated absence management as a core capability, helping carriers simplify the complex process of managing absence to improve engagement and user experience. As the industry leader for core software, FINEOS plans to raise the industry standard in 2021 even further by continually expanding the FINEOS Platform for Employee Benefits.
“Insurers need technology solutions to meet the increased expectations for customer experience and to increase efficiencies and outcomes for key products like Disability and Absence Management,” says Nancy Casbarro , Vice President of Research and Consulting at Novarica. “They’re looking to solution providers like FINEOS for solutions that offer digital solutions for self-service, configurable policy administration, enrollment and claims capabilities all driving greater efficiency, reliable upgrades and long-term system lifecycle support.”
About FINEOS Corporation
FINEOS is a leading provider of core systems for life, accident and health insurers globally with 7 of the 10 largest group life and health carriers in the US as well as 6 of the largest life insurers in Australia. With employees and offices throughout the world, FINEOS continues to scale rapidly, working with innovative progressive insurers in North America, Europe, and Asia Pacific.
The FINEOS Platform provides core administration capabilities including absence management, billing, claims, payments, policy administration, provider management and new business and underwriting; all of which are configurable to operate independently or as FINEOS AdminSuite, an end-to-end core administration suite.
For more information, visit www.FINEOS.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210128005062/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference9.10.2026 19:15:00 CEST | Press release
- Data on ALYFTREK in children ages 2 to 5 years demonstrate recovery of pancreatic function in some children –- Additional abstracts on clinical and real-world evidence on CFTR modulators also presented - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine p
Andersen Consulting udvider med TalentSmartEQ for at fremme lederskab og virksomhedstransformation9.10.2026 18:48:00 CEST | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for humankapital gennem en samarbejdsaftale med TalentSmartEQ, en San Diego-baseret virksomhed, der har fokus på at skabe praktiske, engagerende og handlingsorienterede læringsoplevelser med udgangspunkt i emotionel intelligens (EQ) og lederudvikling. I mere end to årtier har TalentSmartEQ arbejdet sammen med organisationer verden over med henblik på at udvikle ledelseskompetencer ved hjælp af emotionel intelligens og dermed styrke medarbejderengagement, teamwork og de samlede resultater. Virksomheden kombinerer forskningsbaserede metoder med praktiske læringsforløb, vurderinger, coaching og skræddersyede programmer, der skal omsætte opbygningen af emotionel intelligens til vedvarende ændringer i adfærden på arbejdspladsen. Som førende aktør i branchen samarbejder TalentSmartEQ med organisationer lige fra Fortune 500-virksomheder til offentlige myndigheder og privatejede virksomheder. "Organisationer stiller stadig større krav til dere
Verdant Rock Receives A (low) Financial Strength Rating from Morningstar DBRS, Adding a Second International Investment-Grade Assessment9.10.2026 16:00:00 CEST | Press release
Verdant Rock now holds Financial Strength Ratings from both Fitch Ratings and Morningstar DBRS, providing counterparties with dual-agency confirmation and reinforcing the security architecture behind each financial guarantee Verdant Rock Limited, a Bermuda Monetary Authority-regulated Class 3B insurance company, has received an A (low) Financial Strength Rating from Morningstar DBRS. The rating reflects Verdant Rock’s financial strength and its capacity to meet policyholder obligations as an investment-grade financial guarantor for Emerging Markets credit. Morningstar DBRS is a global credit rating agency with coverage across North America, Europe, Asia, and Latin America. Its assessment of Verdant Rock reflects the company’s strong projected earnings ability, robust risk profile, sound liquidity, and good capitalization. Morningstar DBRS also assigned an A (low) Issuer Rating to Verdant Rock. The rating follows Verdant Rock’s BBB+ Long-Term Insurer Financial Strength Rating with a Sta
Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions9.10.2026 15:17:00 CEST | Press release
We think Gartner recognizes Tecnotree's open, governed approach to agentic AI as operators make AI the engine of their revenue operations Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, today announced that Gartner has positioned it as a Visionary in the first-ever Magic Quadrant for AI-Enabled CSP Marketing and Sales Solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009905430/en/ Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions A new category for a new operating model. CSPs are fighting saturated markets, rising acquisition costs, and accelerating churn. They are responding with AI-driven automation across the full revenue cycle, from segmentation and campaigns to lead management, CPQ, and renewals, increasingly executed by autonomous agents. According to us, Gartner creation of this Magi
Positive New Data on Corcym’s Perceval Plus Sutureless Aortic Heart Valve Encompasses up to 7-Year Follow-up9.10.2026 15:15:00 CEST | Press release
Data Presented at Annual Meeting of European Association for Cardio-Thoracic Surgery (EACTS), Along with 6 Perceval Plus E-PostersEACTS Also Marks Commercial Launch of TriMemo and Memo 4D Curve, Innovative Repair Devices for Tricuspid and Mitral Valves Corcym, a global medical device company dedicated to cardiac surgery, today announced that positive mid-term data from a sub-analysis of its Perceval Plus sutureless aortic heart valve as part of its MANTRA clinical trial was featured in an oral presentation today at the annual meeting of the European Association for Cardio-Thoracic Surgery (EACTS). The study is the longest follow-up available for Perceval Plus and the FREE tissue treatment from an international multicenter study, and demonstrated excellent durability, safety and quality of life improvements. Perceval Plus is the only sutureless and collapsible aortic surgical heart valve. Its unique design performs in any surgical scenario and is optimal for endoscopy and robotics. The
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
